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In 1987, some 30 years ago, the journal Cardiovascular Drugs and Therapy was founded by two 
eminent cardiologists, Henry N. Neufeld and Lionel H. Opie. It was initially sponsored by the 
International Society for Cardiovascular Pharmacotherapy with the aim of promoting world-wide 
research and development. The Journal was formed in response to the need to bridge the gap 
between the pharmaceutical industries and academic and practicing cardiologists. The recognition of 
this need turned out to be highly prescient, as communication between these groups remains crucial 
to the development of new cardiovascular drugs and therapies today. 
 
The Journal was founded at an exciting time in cardiovascular medicine, when the development of 
acute coronary care and noninvasive diagnostic methods for earlier disease detection were leading 
to a decline in mortality from coronary heart disease for the first time. Reassuringly, these trends 
have continued. At that time, cardiovascular disease was recognized as the primary cause of death in 
Western societies. Since then, however, the disease has become no longer the preserve of the 
affluent West, and remains the number one killer globally. This highlights the need for revolutionary 
new approaches to treating cardiovascular disease. 
 
Looking back at the very first issue of Cardiovascular Drugs and Therapy it is notable that it included 
a focussed section on ACE inhibitors[1]. The first ACE inhibitor had been isolated from the venom of 
the Brazilian pit viper Bothrops jararaca about 10 years previously, and small molecule inhibitors 
subsequently designed by a process of rational design. Inhibition of the renin-angiotensin pathway 
remains one of the cornerstones of cardiovascular medicine, as outlined by recent reviews including 
those appearing within in this Journal[2]. Interestingly, LCZ696 (Valsartan plus sacubitril), one of the 
newest cardiovascular drugs of the current era[3], in addition to inhibiting the enzyme neprilysin 
targets the same angiotensin pathway. 
 
The phenomenon of ischaemic preconditioning was discovered is 1987, the same year as the Journal 
was founded, and the two have evolved continuously and in parallel ever since. In this issue, one of 
the leading researchers in this area, Robert Kloner takes a step back to look at recent progress in this 
important area, and the exciting new directions with the most potential for moving this field 
forward[4]. 
 
As populations grow, and environmental effects such as diet, smoking frequency and air pollution 
evolve, the spectrum and presentation of cardiovascular diseases varies. It is increasingly evident 
that, despite the impressive benefits of emerging cancer therapies, a substantial proportion of 
today's successfully-treated cancer patients may become tomorrow's cardiac patient. The group of 
Prof Derek Yellon of the Hatter Cardiovascular Institute in London, reviews the mechanism of 
anthracycline cardiotoxicity, and potential methods being developed in order to protect against this 
injury[5]. This group also offer a review of the topic of cardioprotection in relation to exosomes, 
endogenous nanoparticles which had only recently been named at the time the Journal began, but 
which have seen a monumental explosion of interest in recent years[6]. 
 
Thirty years ago mitochondria were primarily regarded purely from the point of view of ATP 
generation. They are now known to play a central role in cellular survival, and cardiac health and 
disease, and understanding how their shape and activity is regulated has become a question of 
major importance. Derek Hausenloy and co-workers examine this rapidly evolving field in their 
review[7]. 
 
Protein quality control is increasingly recognized as critical in maintaining cellular homeostasis and 
function. Recent evidence suggests it may be a causal mechanism for the development of 
atherosclerosis and heart failure. Minamino et al. review the mechanisms of protein quality control 
and how they may be involved in cardiovascular complications induced not only by anthracyclines, 
but also by anti-cancer drugs such as tyrosine kinase inhibitors and proteasome inhibitors[8]. 
 
It is hoped that this selection of reviews on key topics illustrates the progress that has been made in 
cardiovascular research over the past 30 years, and the new areas opening up as a consequence 
both of changing landscape of disease, and revolutions in research.  
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